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The prevalence of diabetes mellitus (DM) is increasing worldwide, a consequence of the alarming rise in obesity and metabolic
syndrome (MetS). Oxidative stress and inflammation are key physiological and pathological events linking obesity, insulin
resistance, and the progression of type 2 DM (T2DM). Unresolved inflammation alongside a “glucolipotoxic” environment of the
pancreatic islets, in insulin resistant pathologies, enhances the infiltration of immune cells which through secretory activity cause
dysfunction of insulin-secreting 𝛽-cells and ultimately cell death. Recent molecular investigations have revealed that mechanisms
responsible for insulin resistance associated with T2DM are detected in conditions such as obesity and MetS, including impaired
insulin receptor (IR) signalling in insulin responsive tissues, oxidative stress, and endoplasmic reticulum (ER) stress. The aim of
the present review is to describe the evidence linking oxidative stress and inflammation with impairment of insulin secretion and
action, which result in the progression of T2DM and other conditions associated with metabolic dysregulation.
1. Introduction
The obesity epidemic and the consequent development of
metabolic syndrome (MetS) are an increasingly significant
health problem, associated with reduced life span and quality
of life. Insalubrious diet habits, physical inactivity, urbani-
sation, genetic predisposition, and aging contribute to the
higher prevalence of these diseases across populations world-
wide. MetS is a term given to a condition associated with the
collection of a series of risk predictors that are associated with
metabolic diseases including obesity, cardiovascular disease,
diabetes mellitus (DM), and more recently dementia [1–3].
These risk factors include changes in plasma triglycerides, low
density lipoprotein (LDL) to high density lipoprotein (HDL)
cholesterol ratio, high fasting glycaemia, and alterations in
blood pressure and adiposity [1, 2]. Aberrant lipid and glucose
metabolic turnover, and decreased action or subsequent
dysfunctional release of insulin, is central to the development
and progression of diabetes, particularly in relation to the
onset of insulin resistance which is associated with impaired
insulin signalling in insulin sensitive target tissues including
muscle, liver, and adipose tissue.
Oxidative stress and inflammation are key players in
insulin resistance progression and the establishment of type
2DM (T2DM). As obesity is established and body weight
increases with age, a parallel state of chronic inflammation,
characterised by an elevation of proinflammatory cytokines,
can induce changes and switch the metabolic homeostatic
set points, leading to T2DM [4]. In response to inflam-
matory stimuli, an increased migration and infiltration of
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macrophages may occur in peripheral tissues, including
pancreatic islets, liver, and adipose tissue, so that cell and
tissue malfunction results including reductions in insulin
secretion [5–7].
Elevated energy intake and/or low expenditure (insuf-
ficient physical activity) leads to abnormal nutrient metab-
olism that culminates in the accumulation of intracellular
and extracellular lipids contributing to lipotoxicity, a process
widely reported for T2DM. Notably, increasing apolipopro-
tein E (ApoE) and related isoforms (E4, E3, and E2) have
been correlatedwith increasing bodymass [8] and specifically
ApoE4 was associated with increasing levels of serum insulin
and glucose [9–11]. Furthermore, it has been demonstrated
that mice deficient in ApoE4 had reduced lipid deposition
in the liver and adipose tissue, which eloquently connects
dysfunctional lipid metabolism to obesity [12]. Additionally,
the formation and accumulation of ceramide, an important
lipid metabolite, have also been associated with several
chronic diseases, including cardiovascular disease, obesity,
and T2DM [13]. Interestingly, it has recently been shown that
ceramide accumulation may impact energy balance through
induction of lipotoxicity and ER stress in the hypothala-
mus [14]. Continuous overnutrition (i.e., high glucose and
lipid diets) leads to glucotoxic and lipotoxic effects or, in
combination over a chronic period, glucolipotoxic condi-
tions. Importantly, glucolipotoxicity affects mitochondrial
function including impairment of electron transport chain
activity, leading to increased reactive oxygen species (ROS)
production which, in turn, triggers inflammation in both
peripheral tissues and insulin secreting 𝛽-cells. Furthermore,
excess nutrients, such as abnormally high glucose and fatty
acids, promote endoplasmic reticulum (ER) stress, which
reduces the ability of 𝛽-cell to efficiently secrete insulin,
contributing to the increased inflammation, oxidative stress,
and elevated circulating nutrients including glucose. Mech-
anistically, excessive generation of ROS can affect DNA,
protein, and lipid integrity and consequently lead to cell
death. Although it is still difficult to attribute causal effects of
oxidative stress and inflammation in relation to each other in
DM, both play a significant role and mediate the progression
ofDM.Asmuch as novelmolecular approaches have revealed
several different pathways and targets of insulin secretion
and action during progression of T2DM, in this paper we
examine the commonalities and differences in metabolic and
molecular processes that emanate from the extrapancreatic
periphery towards the pancreatic 𝛽-cell leading to the dys-
functions that characterise T2DM.
2. Insulin Resistance
Obesity and MetS are correlated metabolic diseases asso-
ciated with chronic low-grade inflammation. The inflam-
matory response is well characterised as an adaptive and
protective process for multicellular organisms to oppose
infections, and it also permits tissue repair [15]. On the other
hand, in conditions such as obesity,MetS, andT2DM, chronic
inflammation induces changes in metabolic function and
alters homoeostatic set points, which exacerbate the disease.
For instance, the link between the metabolic disturbances,
such as high lipid profile and development of atherosclerosis,
was first demonstrated in 1973 and classified as a catastrophic
disease [16]. However, the relationship between obesity and
T2DM was only illustrated in vivo twenty years later, in
1993 [17]. Here, it was reported that adipose-derived tumour
necrosis factor alpha (TNF-𝛼) levels in mice were increased
during the advancement of obesity, but when TNF-𝛼 was
neutralised, insulin sensitivity was improved [17].
Later, it was found that the mechanism by which TNF-
𝛼 suppressed insulin receptor (IR) activity involved serine
phosphorylation of IRS1 (insulin receptor substrate-1), an
important signalling protein immediately downstream of the
IR [18]. TNF-𝛼 attenuated insulin-mediated modifications of
cell function andmetabolism, demonstrating the importance
of this cytokine in linking adipose tissue inflammation with
insulin resistance. In normal conditions, binding of insulin to
the IR induces the production of triacylglycerols from diet-
derived fatty acids and glucose-derived glycerol 3-phosphate.
Therefore, insulin promotes a simultaneous uptake of lipids
and glucose into adipose tissue in vivo. Any impairment of
these interactions will lead to a surplus of circulating glucose
and fatty acids, which is predominantly observed in T2DM.
Conversely, in periods of fasting, starvation, and strenuous
exercise, adipose tissue will release nonesterified fatty acids
(NEFAs) and glycerol into the vasculature, under the action
of various lipases to replenish the plasma nutrient levels and
spare glucose for brain function in these conditions.
The adipose tissue is also able to synthesise and
releases adipokines into the circulation, including leptin and
adiponectin. Leptin was demonstrated to modulate satiety
and energy balance, an effect dependent on neuroendocrine
signalling in the hypothalamus [19]. Similarly, adiponectin
was shown to promote insulin sensitivity, and mice with
adiponectin-deficiency are highly insulin resistant [20]. In
addition, elevated basal adiponectin levels may be associated
with a reduced risk of T2DM [21]. Therefore, adipokines are
considered to modulate insulin sensitivity in the key insulin
target organs, including liver and skeletalmuscle. However, in
chronic expansion of adipose tissue, low-grade inflammation
occurs with consequent infiltration of immune cells that
can lead to a reduction in adipokine secretion, subsequently
resulting in systemic insulin resistance.
2.1. The Role of Unresolved Inflammation in Extrapancre-
atic Periphery. Macrophage accumulation in obese adipose
tissue is common, and here they secrete proinflammatory
cytokines that modulate adipose tissue glucose and lipid
metabolism [20]. Tateya et al. demonstrated that F4/80+
CD11b+ macrophages were present in adipose tissue of lean
mice and represented 5% of the stromal vascular fraction.
However, this figuremay be increased by up to 30% in adipose
tissue of obese mice [20]. The infiltration of these immune
cells into adipose is significant asmacrophage-derivedTNF-𝛼
and interleukin-6 (IL-6) can impair lipoprotein lipase activity
and thus may increase blood triacylglycerol concentration.
Furthermore, TNF-𝛼 can promote hormone-sensitive lipase
activity in adipose tissue, which may result in release of
NEFA into the blood, while concomitantly reducing insulin-
stimulated glucose uptake via impaired insulin signalling as
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outlined above. Consequently, these effects would encourage
increased plasma lipid levels, against the backdrop of reduced
lipid disposal by adipose tissue, which perpetuates lipotoxic-
ity in the T2DM condition.
Increasing plasma concentrations of NEFA and ceramide
are important in connecting nutrient metabolism with
inflammation. Accordingly, ceramide was shown to induce
IL-1𝛽 secretion from macrophages in obese individuals and
high-fat diet (HDF) fed animals [22], while at a mechanistic
level, NEFAs activated the NOD-like receptor family and
pyrin domain containing 3 (NLRP3) inflammasome in hae-
matopoietic cells and promoted insulin resistance [23].
A recent key publication revealed that activation of the
macrophage inflammasome using islet amyloid polypep-
tide (IAPP) was dependent on both glucose and fatty
acid metabolism [24], leading to subsequent production of
inflammatory cytokines IL-1𝛽 and IL-18. A follow-up study
demonstrated that both glucose and minimally modified low
density lipoprotein (mmLDL), both of which are elevated
in T2DM [25], were required for full IAPP-mediated acti-
vation of NLRP3 inflammasomes in bone marrow-derived
macrophages. Furthermore, Toll-Like Receptor-4 (TLR4)
downstream pathways were found to be critical for transduc-
ing these signals [24].
2.2. The Central Role of Infiltrating Macrophages. The acti-
vation status of infiltrating macrophages is important in the
progression of metabolic diseases. Two different polarisation
states, M1 (proinflammatory) and M2 (anti-inflammatory),
have been characterised so far. The proinflammatory M1
form is stimulated by proinflammatory mediators such as
lipopolysaccharide (LPS), TNF-𝛼, and interferon-𝛾 (IFN-𝛾).
These macrophages produce and secrete TNF-𝛼, IL-1, and
IL-6, enhancing the inflammatory response. Conversely, the
M2 anti-inflammatory phenotype has significantly reduced
proinflammatory characteristics, and these cells release high
levels of anti-inflammatory cytokines, for instance, IL-10.
Interestingly, ingestion of a diet high in lipid content was
shown to polarise Kupffer cells of the liver towards the
M1 phenotype [26]. These cells are resident macrophages
of the liver and this polarisation was associated with the
pathogenesis of obesity-induced insulin resistance and fatty
liver disease [26].
In addition, TNF-𝛼 production by M1 macrophages in
the liver can promote increased hepatic glucose output
via gluconeogenesis and by decreasing glycogen content,
while simultaneously enhancing lipid production and storage
through inhibition of intracellular lipases and providing
intracellular fatty acids for triacylglycerol synthesis. Thus,
elevated TNF-𝛼 in the obese liver may increase blood glucose
levels and promote fatty liver disease [26]. However, there
is a heterogeneous population of immune cells in the liver,
but Kupffer cells, in particular, are believed to facilitate both
insulin resistance and hepatic steatosis and steatohepatitis,
which are associated with increased c-JunN-terminal protein
kinase (JNK1) activation and consequent lowering of heat
shock protein (HSP) pathways, which are anti-inflammatory
[27]. Interestingly, chemical removal of these cells can
improve insulin sensitivity during consumption of a high-
fat diet. Therefore, the delicate balance and adaptability of
macrophages between M1 and M2 phenotypes are important
to liver metabolism. Consequently, maintenance of the M2
phenotype over M1 phenotype is desirable in the liver and
key for appropriate glucose and lipid production along with
subsequent release.
Taken together, these data suggested that the high
nutrient milieu observed in T2DM may activate circulat-
ing macrophages that could possibly lead to chronic low-
grade inflammation, which is a hallmark of obesity and
T2DM. Moreover, interactions of macrophages and pro-
duction of proinflammatory cytokines can negatively affect
metabolic processes in tissues that are physiological tar-
gets for insulin. These inflammatory exchanges may lead
to hyperglycaemia and dyslipidaemia, which are important
characteristics indicative of obesity, T2DM, and MetS.
2.3. Impaired Insulin-Signalling Pathways. Insulin resistance
does play a key role in the pathogenesis and progression
of chronic metabolic diseases that are proinflammatory in
nature, such as obesity, T2DM, brain dysfunction, and heart
disease [28]. Insulin resistance is an important health issue
since it flourishes silently much before the onset of such
metabolic manifestations [15, 29]. Insulin resistance refers to
impaired or failed intracellular transduction of the insulin-
mediated signalling cascade in sensitive tissues, especially the
liver, skeletal muscle, and adipose tissue. This leads to an
impaired disposal of blood glucose along with an elevated
hepatic glucose output, both combining to result in elevated
plasma glucose. High levels of glucose promote an increased
demand on pancreatic 𝛽-cells to synthesise and secrete
insulin so as to reestablish appropriate blood glucose levels.
Since this compensatory mechanismmay reduce glucose lev-
els during prediabetes and early stages of DM development,
chronic and persistent insulin resistance exposes the 𝛽-cells
to an excess of glucose and lipids, thereby promoting 𝛽-cell
dysfunction, failure, and death. However, insulin sensitivity
can be improved using pharmacological drugs, control of
diet, and regular exercise [30]. To investigate themechanisms
leading to insulin resistance, one must first understand
insulin signalling in the context of normal insulin-mediated
interactions that are observed in nondiabetic models.
2.3.1. Disruption of Insulin Receptor (IR) and Insulin Receptor
Substrate (IRS). Insulin is released into the vasculature by 𝛽-
cells in response to elevated blood glucose levels, following
ingestion of food. Insulin elicits its anabolic effects via
association with the transmembrane IR, present in target
tissues. These key membrane-bound receptors are present in
cells that store surplus carbohydrate in the form of glycogen
(liver and muscle) or as triacylglycerol (adipose tissue).
The IR is composed of four peptide subunits (two 𝛼-chain
subunits and two 𝛽-chain subunits) and is a heterotetrameric
tyrosine kinase receptor.The interaction with insulin induces
autophosphorylation of the receptor at tyrosine residues
(Tyr1158, Tyr1162, and Tyr1163) [31], and this initiates the
recruitment and phosphorylation of the intracellular adapter
proteins (IRS).
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Thirteen different IRS isoforms have been described, but
isoforms 1 and 2 have been studied extensively since they
are widely distributed among different cell types and are
mainly activated in skeletal muscle [32], which is responsible
for approximately 75% of insulin-stimulated blood glucose
uptake in the body [32, 33]. Phosphorylated IRS1, to a lesser
extent IRS2, induces activation of the PI3K lipid kinase via
binding with the p85 regulatory subunit of PI3K. Activated
PI3K converts phosphatidylinositol 3,4-bisphosphate (PIP2)
to PI(3,4)P2 and phosphatidylinositol 3,4,5 triphosphate
(PIP3), via the p110 catalytic subunit. This conversion acti-
vates 3-phosphoinositide-dependent protein kinase 1 (PDK1)
that subsequently recruits and phosphorylates protein kinase
B (pAkt) at the plasma membrane. PDK1 can also activate
atypical protein kinase C (aPKC)which also regulates glucose
metabolism [34]. Downstream of these interactions, pAkt
has over 100 substrates that regulate many cellular processes
including cell proliferation, differentiation, endocytosis, sur-
vival, and glucose homeostasis [35]. Three isoforms of Akt
exist, and Akt2 is recognised as the most abundant in insulin
sensitive tissues. Interestingly, when Akt2 was deleted in
knockout mice, increased insulin resistance was observed
illustrating the important physiological role played by Akt2
in mediating glucose homeostasis [36]. Mechanistically, Akt
is an important regulator of translocation of GLUT4 vesicles
to the plasmamembrane, which is critical for the intracellular
uptake of free glucose in insulin sensitive tissues [37, 38].
Appropriate insulin signalling may be interrupted
because of either genetic alterations or physical changes to
any of the aforementioned signalling nodes, and this may
manifest as insulin resistance. Mutations and serine hyper-
phosphorylation of IRS proteins are especially associated
with development of insulin resistance, as they are thought to
decrease the interaction of IRS with PI3K (reviewed by [39]).
Previously, homozygous disruption of IRS1 transcription
led to mild insulin resistance [40], while IRS2-knockout
mice exhibited severe insulin resistance [41]. Furthermore,
in T2DM patients, many precise amino acid substitutions in
IRS1 proteins are believed to alter protein function, but some
of these substitutions have been controversial. For example,
researchers have reported that Gly972Arg is a common
polymorphism in T2DM patients [42, 43], but others have
failed to observe similar findings in other T2DM populations
[44]. In addition, hyperphosphorylation of serine at residues
Ser302, Ser307, Ser612, and Ser632 in IRS1 was suggested to be
responsible for increased insulin resistance in animal models
[39]. In fact, uncontrolled proinflammatory cytokines syn-
thesis and secretion, and activation of proinflammatory
signalling proteins activation, such as tumour necrosis factor
alpha (TNF-𝛼) and the isoform 1 of c-Jun N-terminal protein
kinase (JNK1) in response to adipose tissue expansion,
can induce serine hyperphosphorylation in IRS1 [18, 45],
especially at residue Ser636 (Figure 1). However, it is not
entirely knownwhich specific serine residues or combination
thereof require hyperphosphorylation to elicit the insulin-
resistant phenotype, as excessive phosphorylation at Ser337
and Ser636 has been demonstrated in muscle samples from
patients with metabolic syndrome, but not at Ser307, Ser789,
or Ser1101 as reported by others [45]. Moreover, serine hyper-
phosphorylation at residue Ser312 marks IRS1/2 for
degradation, which dampens the IR-mediated signalling
relay. Taken together, these data demonstrate the complexity
of the role played by IRS proteins, but also their importance
in modulating insulin resistance.
2.3.2. Disruption of PI3K Function. Dysregulation of PI3K
activity is another molecular mechanism that may attenuate
insulin signal transduction. PI3K lipid kinases are composed
of two polypeptide subunits, one p110 catalytic subunit and
a p85, p65, or p55 regulatory subunit, and these proteins
are classified according to the combination of both domains.
Importantly, a balance between the active heterodimer and
the individually expressed inactive regulatory domains exists
in the cytosol. This system allows for tight regulation and
appropriate activation of the PI3K-Akt pathway, where the
regulatory domains compete for IRS binding sites with the
active heterodimer [39]. However, it was suggested that
excessive expression of individual regulatory domains (e.g.,
p85) in skeletal muscle was responsible for blocking the
binding of the signalling heterodimer with IRS in pregnancy-
induced insulin resistance [46]. Conversely, in mice with
the genetic deletion of p85 in the liver, improved hepatic
and peripheral insulin sensitivity was shown [47], which
eloquently demonstrates the impact of dysfunctional PI3K-
signalling on insulin resistance.
Alternatively, decreased IR expression or desensitisation
to the insulin ligand may occur and may be involved
in the insulin resistant phenotype. The precise molecular
mechanisms are not fully understood, but some studies have
shown that chronic hyperglycaemia and prolonged hyper-
insulinaemia, together with increased ROS/RNS levels, may
affect IR gene expression via dysfunction of key transcription
factors such as high mobility group AT-hook 1 (HMGA-1)
[48]. Importantly, under normal conditions these signalling
pathways are regulated by a negative-feedback mechanism
to control IR sensitivity [49]. Hyperinsulinaemia is a key
pathological characteristic of insulin resistance but it is not
clear whether this is a cause or a consequence of insulin
resistance. Chronically elevated insulin levels can reduce IR
expression in the liver [50, 51] and primary adipocytes [49]
and in the kidney [52], and it is a possible mechanism that
exasperates development of insulin resistance. In addition,
it was suggested that decreased IR expression in the kidney
of insulin resistant rats increased sodium reabsorption in
the proximal tubule [52], and this salt retention promoted
hypertension, which is closely associated with cardiovascular
disease, obesity, diabetes, and insulin resistance.
2.3.3. Hyperglycaemia Negatively Impacts Insulin-Responsive
Tissues. Interestingly, in skeletalmuscle excessively increased
carbohydrate levels can also decrease insulin association with
the IR and cause decreased IR expression [53]. Supporting
experiments that mimicked the milieu of T2DM showed
that high glucose and high insulin in combination reduced
insulin binding to the IR in adipocytes [54]. These ex vivo
treatments also decreased the expression of IRS1 and IRS2,














































Figure 1: Insulin resistance and the role of inflammation. Overnutrition leads to high levels of lipids and glucose and overtime development
of obesity and metabolic syndrome (MetS), ultimately causing chronic low-grade inflammation. High nutrients can modulate insulin
resistance by altering the insulin-signalling cascade through changes in IRS1, PI3K, and AKT phosphorylation. High lipids can also promote
inflammation through generation of ceramide, and high glucose increases overall oxidative stress. During T2DM progression the insulin
resistant tissues promote the exhaustion of insulin secreting 𝛽-cells, which activates defensive mechanisms leading to lower insulin release.
further demonstrating inhibition of insulin signal transduc-
tion, while these treatments also impacted negatively Akt
sensitivity.This latterwork revealed the effects of high glucose
and insulin on inducing postreceptor defects. However, the
precise molecular processes by which elevated carbohydrates
promote insulin resistance are not fully understood but are
believed to involve modifications of postreceptor molecules
such as IRS, PI3K, and Akt.
For instance, increased production of ROS/RNS or
decreased antioxidant capacity as a result of increased carbo-
hydratemetabolism in the peripherymaymodify phosphory-
lation of these signalling proteins and promote deactivation.





) reduced insulin signalling and conse-





Ser307 phosphorylation in IRS1, leading to reduced IRS1
protein expression and increased IRS proteolysis [55, 56].
In addition to oxidative stress, proinflammatory cytokines,
includingTNF-𝛼, can also induce Ser307 phosphorylation and
thereby decrease the interaction of IRS1 and the IR, impairing
signal transduction in a similar manner. Thus, it is not a
coincidence that, in obesity and T2DM patients, proinflam-
matory cytokines and plasma nutrients are chronically ele-
vated, compared to healthy and lean subjects [29, 57]. When
these processes are coupled with elevated oxidative stress,
a proinflammatory environment is maintained, which leads
to the unresolved inflammation and chronic activation of
proinflammatory signalling pathways activation (e.g., nuclear
factor kappa B (NF-𝜅B) and JNKs). As a consequence, the
progression of the disease occurs along with time (several
years), and immune cell recruitment occurs in insulin target
tissues, such as liver and adipose tissue, but also in tissues not
directly associated with insulin action, including the islet [5].
3. 𝛽-Cell Dysfunction in Diabetes
The major function of the pancreatic 𝛽-cell is to couple
nutrient sensing and subsequent metabolism to insulin
release. Therefore, acute exposure of 𝛽-cells to nutrients,
such as glucose, lipids, and some amino acids, promotes
insulin secretion. However, incessant exposure to elevated
glucose and lipids is known to have detrimental effects on
pancreatic 𝛽-cell insulin secretion [58] and is correlated
with onset of insulin resistance in the periphery [59]. These
elevated nutrient levels can initially result in enhanced
metabolismof𝛽-cells and subsequent hyperinsulinaemia, but
chronic exposure induces oxidative stress that may cause 𝛽-
cell dysfunction and even 𝛽-cell death [60]. Consequently,
decreased insulin output from this process due to𝛽-cell death
compounds glucolipotoxicity and initiates the deleterious
vicious cycle observed in T2DM (Figure 2).
3.1. Oxidative and Nitrosative Stress: A Role in Glucolipo-
toxicity. Emerging evidence has suggested that the respon-
siveness of pancreatic 𝛽-cells to glucose, the major insulin
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Figure 2: 𝛽-cell dysfunction in diabetes. Excessive glucose levels lead to high insulin production in 𝛽-cells. Increased insulin synthesis
promotes endoplasmic reticulum (ER) overload, unfolded protein response (UPR), and ER stress. Prolonged ER stress leads to apoptosis and
IL-1𝛽 release through inflammasome activation. Local proinflammatory cytokines induceNF𝜅B activationwhich promotes proapoptotic gene
expression changes.These changes in gene expression favour Bax/Bak oligomerization and mitochondrial outer membrane permeabilization
(MOMP), consequently leading to apoptosis. In addition, NF𝜅B-dependent iNOS activation triggers ER stress and apoptosis as well.
Lipotoxicity promoted by NEFAs also leads to 𝛽-cells ER stress via different mechanisms, including reactive oxygen and nitrogen species
(ROS/RNS), calcium depletion (Ca2+), and ER to Golgi protein traffic impairment.
secretagogue, is dependent on the acute regulation of intra-
cellular and, in certain cases, extracellular ROS/RNS [61, 62].
Increased glycolytic flux enhances oxidative phosphorylation
andATPgeneration, with the concomitant elevation of super-
oxide (O2
∙) anion release from the electron transport chain
[63]. Moreover, through the pentose phosphate pathway
the conversion of glucose to pentose is an initial response
to deviate glucose carbon away from excessive glycolysis
and oxidative phosphorylation. However, this pathway can
also produce NADPH which via NADPH Oxidase (NOX)
activity leads to increased O2




formation in the 𝛽-cell [60]. Persistently high glucose can
lead to the generation of ROS via othermechanisms including
glucose autoxidation and generation of advanced glycated
end products (AGE), which exasperates intracellular ROS
levels [64].
Superoxide formation is considered the first stage in
a ROS-generating cascade that produces other forms of
ROS/RNS [61]. Superoxide can be converted into the less




, via superoxide dis-
mutase (SOD), which can subsequently generate the highly
reactive hydroxyl free radical (OH∙) by the iron-catalysed
Fenton reaction [61, 63, 65]. Furthermore, the reaction
of O2
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with nitrite forms the highly reactive nitrogen free radical,
peroxynitrite (ONOO−) [61], which induced significant cel-
lular damage in rat and human islets in vitro [66, 67] and
has been found to be elevated in the islets of NOD mice
[68]. For instance, the function of antioxidants in 𝛽-cells





ROS/RNS promote oxidative damage to DNA, proteins,
and lipids through nitration, carbonylation, peroxidation,
and nitrosylation modifications. These molecular alterations
may affect enzyme activity, ion channel transport, or recep-
tor signal transduction and consequently dysregulate gene
expression and induce apoptosis [61]. It is well established
that ROS-mediated activation of JNK signalling leads to
decreased insulin secretion via nucleocytoplasmic transloca-
tion of pancreatic and duodenal homeobox-1 (PDX-1), a key
transcription factor that binds to the insulin promoter and
induces insulin expression [69].
ROS/RNS may also play a dual role in regulating insulin
secretion, where excess is detrimental but lower levels aid
insulin release. It appears that low levels are required to
act as a second messenger for glucose stimulated insulin
secretion (GSIS). NO was shown to regulate the interaction
between glucokinase and insulin secretory granules [70] and
also enhanced granule exocytosis through S-nitrosylation of
syntaxin 4, a protein involved in vesicle-plasma membrane




levels were suggested to
positively regulate mitochondrial Ca2+ influx [72], a process
that is important for enhancing tricarboxylic acid cycle
activity, which is amajor driver of the second phase of insulin
release [73]. The specific downstream targets of ROS/RNS
that positively and/or negatively regulate insulin secretion are
still unclear, but possible candidates include various tyrosine
kinase receptors, transcription factors, and other protein
kinases/phosphatases [62]. Consequently, ROS/RNS may
additionally regulate important cell signalling pathways such
as PI3K/Akt, mitogen-activated protein kinases (MAPK),
JNK, andNF-𝜅B that govern cell proliferation, inflammation,
and cell survival.
3.2. Antioxidant Systems. Pancreatic 𝛽-cells have a high
metabolic activity but are vulnerable to oxidative stress as
they possess reduced antioxidant levels including glutathione
peroxidase (GPx) and catalase [61, 65], although they do
express other antioxidants including glutaredoxin and thiore-
doxin [61]. However, oxidative stress occurs in 𝛽-cells as
a consequence of either excessive ROS/RNS production
or a failure of antioxidant species to effectively neutralise
increasing ROS/RNS levels. For instance, overexpression of
SOD sensitised 𝛽-cells to cytokine-mediated apoptosis [74],
while enhanced expression ofGPxprotected islet𝛽-cells from
ribose-induced intracellular peroxide production [75]. In
addition, antioxidant supplements such as taurine and tempol
[76], as well as amino acids with antioxidant properties (e.g.,
glutamine and arginine) [77, 78], were also demonstrated to
protect 𝛽-cells.
One of the most important nonenzymatic cellular
antioxidants is glutathione (GSH, L-𝛾-glutamyl-L-cystein-
ylglycine), which is also a cofactor for GPx activity. GSH is a
tripeptide that provides protection from oxidative stress and
inflammation [79, 80], but the de novo synthesis is dependent
on uptake and utilisation of the amino acid glutamine [81].
Glutamine is themost abundant amino acid in the circulation
and is regarded as an important metabolic mediator of
insulin secretion [77, 82, 83]. However, levels were suggested
to be decreased in T2DM patients [84], as well as other
intermediary amino acids and related products, including
nitric oxide metabolites [57]. Glutamine is also important
modulator of cytoprotective proteins, such the Heat Shock
Protein (HSP), which are critical following an oxidative insult
or increased endoplasmic reticulum (ER) stress [77, 85].HSPs
are a large family of related proteins that act as molecular
chaperones which correctly fold or refold proteins damaged
by oxidative processes or the ubiquitin-proteasome system
(UPS) [86]. WhenHSPs are expressed intracellularly they are
considered cytoprotective, and recent work has demonstrated
that HSPs like HSP27, HSP70, and HSP90 reduced oxida-
tive stress and inflammation [81, 85, 87]. Conversely, when
added exogenously, we found that HSP72 reduced 𝛽-cell
insulin secretion, altered cellular bioenergetics, and induced
apoptosis in vitro [88]. We speculate that the pathogenic
extracellular release of HSP70 may occur in the diabetic
setting through muscle wasting, through adipose expansion,
or via necrotic destruction of neighbouring 𝛽-cells. However,
the precise clinical impact and the molecular mechanisms
leading to these proapoptotic effects are currently still under
investigation by the authors.
Excessive oxidative and nitrosative stresses also stimulate
the expression of heme oxygenase-1 (HO1), which is also
known as HSP32 [59], as HO1 is a member of heat shock
protein family. HO1 degrades prooxidant haeme moiety into
equimolar quantities of biliverdin-IX𝛼, carbon monoxide
(CO), and ferrous iron (Fe2+). Biliverdin-IX𝛼 can then be
converted into the antioxidant bilirubin, further protecting
cells from oxidative insult [59, 89]. On the other hand,
simultaneous production of CO and Fe2+ as by-products of
the reaction may impact 𝛽-cell insulin secretion [59, 89].
While CO gas has been suggested to positively regulate
insulin secretion in intact mouse islets through mobilisation
of cAMP and cGMP, increased iron load has been suggested
to be a key participant in DM and was associated with
impaired insulin elimination from the liver, reduced insulin
secretion, and attenuated insulin action and glucose transport
in adipose [59]. The full role of iron overload is beyond
the scope of this review, but excessive ferrous iron (Fe2+)
produced against the backdrop of chronically high nutri-
ent levels, increasing metabolism and accordingly elevating
ROS/RNS, may lead to more Fenton reactions occurring
as outlined above and consequently increased formation of
hydroxyl anions. Therefore, further generation of oxidative
stress in this manner may lead to enhanced induction of HO-
1 expression, perpetuating a vicious cycle of ROS production
in the 𝛽-cell.
Taken together, it is clear that excessive, uncontrolled
oxidative stress contributes to pancreatic 𝛽-cell dysfunction,
and therefore research continues to investigate the precise
role of antioxidant agents in mediating 𝛽-cell insulin secre-
tion and survival with a view to become potential treatments
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forDM, particularly in relation toGPxmimetic (e.g., ebselen)
[90]. However, oxidative, nitrosative, and ER stress also play
critical roles in insulin target tissues, such as skeletal muscle
and adipose tissue. Consequently, the oxidative mechanisms
that contribute to dysfunction in these tissues are important.
3.3. Inflammation-Elicited 𝛽-Cell Dysfunction. Proinflamma-
tory cytokines play an important role in 𝛽-cell patho-
physiology. The involvement of TNF-𝛼, IFN-𝛾, and IL-1𝛽
released by infiltrating mononuclear cells in Type 1 diabetes
(T1DM) associated insulitis and 𝛽-cell apoptosis has been
documented (reviewed by [91]). Several studies have shown
that IL-1𝛽 alone, or in combination with TNF𝛼 and IFN-
𝛾, promotes 𝛽-cell dysfunction and death [92–94]. These
early studies only referred to inflammation as an impor-
tant player in T1DM, but not T2DM, since chronic low-
grade inflammation was only later discovered to take place
in T2DM [95, 96]. Interestingly, high glucose and NEFA
promote intraislet production of IL-1𝛽 [97, 98], suggesting
that cytokine-induced𝛽-cell apoptosis could also occur in the
metabolic syndrome and T2DMmilieu.
A hallmark of insulin resistance is the deposition of amy-
loid in the islets and this has been linked to the activation of
NLRP3 inflammasome in local macrophages, triggering IL-
1𝛽processing and release [99]. In this scenario, local release of
IL-1𝛽 could autoinduce its ownproduction through autocrine
stimulation and further attract additional immune cells into
the islet microenvironment. Indeed, macrophage infiltration
increases along with the progression of T2DM in patients and
animal models [100]. A recent study shows that the saturated
fatty acid palmitate is able to activate the innate immunity
via TLR4 and/or myeloid differentiation primary response
gene 88 (MyD88) pathway in islets, promoting macrophage
infiltration and unresolved inflammation [101]. Thus, similar
signalling through cytokine receptors and consequent acti-
vation of proinflammatory transcription factors such as NF-
𝜅B and the signal transducer and activator of transcription-1
(STAT-1) occur in 𝛽-cells, which are ultimately proapoptotic.
However, such hypothesis for 𝛽-cell pathophysiology is still
under debate. For instance, IL-1𝛽 is able to promote NF-𝜅B-
dependent stimulation of the inducible nitric oxide synthase
(iNOS, encoded by NOS2 gene) expression, contributing to
cell death and dysfunction; however, the same effect was
not observed in rodent 𝛽-cells exposed to high glucose. In
addition, exposure of rat or human islets to high glucose did
not increase IL-1𝛽mRNAexpression orNF-𝜅BDNA-binding
activity [102, 103].
Undoubtedly, 𝛽-cell death promoted by the exposure
of proinflammatory cytokines or glucolipotoxicity occurs
through the intrinsic mitochondrial pathway of apoptosis.
This pathway is tightly controlled by members of the B-cell
lymphoma (Bcl) 2 protein family, including antiapoptotic
(Bcl-2, Bcl-XL, Bcl-w, Mcl-1, and BCL2A1) and proapoptotic
(Bax, Bak, DP5, PUMA, Bim, Bid, Bad, and Noxa) members.
Briefly, mitochondrial apoptosis is initiated by Bax translo-
cation and oligomerization with Bak on the mitochondrial
outermembrane.This causesmitochondrial outermembrane
permeabilization (MOMP) and cytochrome c release. In the
cytoplasm, cytochrome c oligomerises with apoptotic pro-
tease activating factor-1 (APAF-1) to form the apoptosome,
which in turn activates the initiator caspase 9. The later
cleaves and activates caspases 3 and 7, which target several
substrates and execute the apoptotic program [104]. Under
healthy conditions, the antiapoptotic members of the Bcl-2
family bind to and inhibit Bax andBak oligomerization.Upon
activation, BH3-only proapoptotic proteins (DP5, PUMA,
Bim, Bid, Bad, and Noxa) promote apoptosis either by
binding and inactivation of antiapoptotic members or by
direct stimulation of Bax and Bak oligomerization [105].
In unstimulated conditions, NF-𝜅B is present in an
inactive form in the cytoplasm, bound to inhibitory 𝜅B (I𝜅B)
proteins. Following IL-1R stimulation, I𝜅B is phosphorylated
at two serine residues (Ser32 and Ser36) by an I𝜅B kinase
complex (IKK). These particular phosphorylation events
target I𝜅B to degradation by the ubiquitin-proteasome system
(UPS), releasing NF-𝜅B to translocate into the nucleus, and
bind target genes promoter regions [106]. Activation of NF-
𝜅B in the 𝛽-cell, through IL-1R signalling, regulates several
genes affected by cytokines [107], including iNOS and anti-
and proapoptotic members of the Bcl-2 family [104]. NF-
𝜅B-dependent iNOS expression promotes nitric oxide (NO)
production and the latter is involved in cytokine-induced 𝛽-
cell secretory dysfunction and apoptosis [108]. In addition,
NF-𝜅B upregulates PUMA, which activates Bax and Bak
oligomerization and contributes to cytokine-induced 𝛽-cell
apoptosis [109].
On the other hand, NF-𝜅B also induces the antiapoptotic
gene BCL2A1 and the mitochondrial antioxidant Sod2 [110,
111]. Thus, NF-𝜅B-dependent gene expression changes are
not purely proapoptotic; however, if sustained (e.g., under
chronic low-grade inflammation), and in conjunction with
additional cytokine-mediated signalling, proapoptotic sig-
nalling prevails over 𝛽-cell defensive systems. One such addi-
tional cytokine-mediated signalling is the JNK/c-Jun stress
kinase cascade. Signalling through this particular pathway
promotes degradation of the prosurvival Mcl-1 [112, 113]
and upregulation of the BH3-only sensitiser DP5 [114]. NO
production also exerts its proapoptotic effects in 𝛽-cells
through activation of JNK pathway and inhibition of the
kinase cascade alleviates NO 𝛽-cell toxicity [108]. Thus, it is
the combination of chronic inflammation and glucolipotoxic
environment of T2DM that causes 𝛽-cell failure and loss in
advanced stages of the disease.
3.4. The Role of Endoplasmic Reticulum (ER) Stress. 𝛽-cell
dysfunction and death are processes that are also connected
to various levels of ER stress [115], particularly because
hyperglycaemia requires increased “work power” by the islets
that need to produce higher amounts of protein (insulin).
Indeed, several physiological and environmental conditions
associated with T2DM have been shown to induce ER stress
in 𝛽-cells. The major systemic event in T2DM, insulin
resistance, imposes a requirement for higher levels of insulin.
𝛽-cells respond to such increased demand by increasing
their cell mass and insulin secretion [116]. Conditions that
require sustained high levels of insulin production, such as
hyperglycaemia, can result in the accumulation of unfolded
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proteins in the ER, since the bulk of chaperones necessary to
prevent protein misfolding does not suffice protein synthesis
so that this unbalanced situation triggers ER stress and,
consequently, the unfolded protein response (UPR) in 𝛽-
cells [117]. Excess nutrients, in the form of high glucose and
NEFA, also promote ER stress [118]. Lastly, the negative effects
of proinflammatory cytokines and oxidative stress can be
mediated by ER stress responses [119].
(Pro)insulin synthesis and folding in 𝛽-cells take place
in the lumen of the ER. However, 𝛽-cells often encounter
situations of ER overload, for instance, when rapid produc-
tion of high amounts of insulin is needed in response to
hyperglycaemia. Under such situations healthy 𝛽-cells can
boost insulin production by more than 10-fold compared to
unstimulated cells, and (pro)insulin alone can account for
about 50% of the total amount of proteins synthesised by
the cell [120]. This can exceed the cellular folding capacity
resulting in accumulation of unfolded (pro)insulin in the ER
lumen, leading to ER stress [121].
In order to alleviate ER stress, cells start the biochemical
program of UPR. UPR is a genetically and biochemically
controlled process that is initiated within the cells in order
to counteract an imbalance in ER homeostasis. It includes
transcription activation of proteins involved in ER-associated
protein folding and degradation, as well as temporary atten-
uation of mRNA translation. This process aims at restor-
ing ER capacity in order to handle protein processing,
folding, and trafficking, reestablishing proteostasis. If this
fails, apoptosis is eventually triggered [122]. Accumulation of
unfolded proteins is sensed by ER transmembrane proteins,
such as the protein kinase RNA-like endoplasmic reticulum
kinase (PERK), inositol-requiring enzyme 1 (IRE1), and the
activating transcription factor (ATF) 6, which initiate the
UPR program. Normally, the ER resident chaperone binding
immunoglobulin protein (BiP) prevents their aggregation.
However, accumulated unfolded proteins compete to BiP
binding sites, allowing ER transmembrane proteins self-
aggregation and activation. Once activated, PERK phospho-
rylates the eukaryotic translation initiation factor 2A (eIF2𝛼)
at (Ser51), resulting in global blockade of protein synthesis
and alleviation of ER overload [123] (Figure 2).
Some mRNAs, however, can bypass translation blockade
by phosphorylated eIF2𝛼. ATF4, a transcriptional factor of
the basic leucine zipper domain (bZIP) family is preferen-
tially translated during these conditions and initiate gene
expression changes associated with UPR [124]. In a similar
way, IRE1 oligomerises in the ER membrane rendering its
activation. It contains an endonuclease domain that, once
activated, excises an intron from the X-box binding protein-1
(XBP-1).This generates the spliced form of XBP-1, which acts
as a transcriptional factor promoting the expression of genes
involved with misfolded protein retrotranslocation into the
cytosol for proteasome degradation as well as ER-associated
protein degradation [125]. High-glucose stimulus has been
shown to induce IRE1 activation both in vivo and ex vivo
(in isolated rodent islets) [126, 127]. ATF6 has a different
mechanism of activation as compared to PERK and IRE1.
Upon BiP disassociation, it migrates to the Golgi apparatus
where it is cleaved and released in the cytosol. Cleaved ATF6
translocates into the nucleus to act as a transcriptional factor
that has XBP-1 as one of its targets [128].
Excessive or prolonged UPR signalling can lead 𝛽-cells to
apoptotic cell death by various different mechanisms. Possi-
bly the most important involves upregulation and activation
of CCAAT-enhancer-binding protein homologous protein
(CHOP). All three branches of ER stress sensing (PERK,
IRE1, and ATF6) have been implicated in activation of CHOP
transcription. However, CHOPmRNA is also regulated at the
translational and posttranslational levels. PERK-dependent
eIF2𝛼 phosphorylation is essential to promote CHOPmRNA
translation in a cap-independent manner (for review see
[129]), similar to ATF4. Furthermore, CHOP protein is only
fully activated by phosphorylation at Ser78 and Ser81 by the
stress kinase P38 MAPK [130]. Once activated, CHOP exerts
its effects in the nucleus where it regulates several apoptotic
genes. In particular, CHOP downregulates Bcl-2 expression,
tilting the balance towards a proapoptotic phenotype [131].
3.5. 𝛽-Cell Fate in UPR: Apoptosis versus Chronic Inflam-
mation. As stated before, in addition to high insulin pro-
duction demand, other physiological hallmarks of T2DM
have been shown to trigger ER stress and 𝛽-cell dysfunc-
tion. Exposure to NEFA, for instance, can activate all three
sensor branches of UPR. Furthermore, overexpression of
BiP alleviates palmitate induced apoptosis in the rodent 𝛽-
cell line MIN6, suggesting that saturated NEFA-induced 𝛽-
cell death is, at least partially, mediated by ER stress [132].
A number of different mechanisms have been proposed to
mediate lipotoxic-induced ER stress in 𝛽-cells. Palmitate
promotes rapid ER calcium depletion and this was linked to
𝛽-cell ER stress [133]. Global proteomics analysis revealed
that Carboxypeptidase E is rapidly degraded in response to𝛽-
cell exposure to palmitate and its degradation both precedes
and is necessary for activation of ER stress response [134]. 𝛽-
cell lipotoxicity has also been implicated in reduction of ER to
Golgi protein traffic, ER overload, and consequent ER stress
[135].Mechanistically, alterations in sphingolipidmetabolism
were implicated in such defective protein trafficking and
inhibition of ceramide synthesis reduced both ER stress and
apoptosis in palmitate treated MIN6 cells [136].
Proinflammatory cytokines, especially IL-1𝛽, can also
induce ER stress and UPR activation in 𝛽-cells. The ability of
this cytokine to promote NF-𝜅B-dependent iNOS expression
and NO production has already been mentioned in this
review. A link between cytokine-induced 𝛽-cell death and ER
stress was established when NO production was shown to
cause ER calcium depletion and ER stress [137]. The mech-
anism was later shown to involve NO-dependent sarcoendo-
plasmic reticulum pump Ca2+ ATPase 2b (SERCA2b) down-
regulation and consequent ER inability to maintain Ca2+
gradient between ER and cytosol, important for ER folding
capacity and homeostasis [138]. Several reports demonstrate
that cytokine signalling activates UPR and ER stress in 𝛽-
cells. Strikingly, cytokine-induced NF-𝜅B activation and 𝛽-
cell death were shown to be, at least partially, mediated
by UPR and CHOP upregulation. In this scenario, CHOP
depletion by siRNA prevented full activation of NF-𝜅B and
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its target proapoptotic genes by cytokines, confirming that
the deleterious effects of proinflammatory cytokines on 𝛽-
cells depend on the activation of the UPR program [139].
A reverse link between 𝛽-cell ER stress and inflammation
has also been recently found.Thioredoxin-interacting protein
(TXNIP), a gene induced by ER stress through the PERK and
IRE1 pathways, activates the NLRP3 inflammasome and IL-
1𝛽 production in human islets, suggesting that the crosstalk
between ER stress and inflammation is a two-way process
[140]. Thus, ER stress is both cause and consequence of
chronic 𝛽-cell inflammation and these two processes are
intimately interconnected. Current and future research in the
area will provide further insights into mechanisms of 𝛽-cell
dysfunction and death and so contribute to the development
of future T1DM and T2DM treatments.
4. Conclusion
DM continues to increase in frequency, presenting a chal-
lenge to health care systems worldwide. Oxidative stress and
inflammation provoked by excessive nutrient availability and
obesity-induced alterations in proteostasis are key factors
associated with DM progression both for the peripheral tis-
sues and for 𝛽-cells within the islets. Using current molecular
tools and related approaches, new studies are advancing
the understanding of the dysfunctional molecular events
in T2DM and may lead to better therapeutic strategies.
Inflammation, ROS generation and regulation of intracellular
signalling are required for homeostasis and survival. How-
ever, excess nutrient availability and low levels of physical
activity lead to an imbalance in metabolic regulation linking
aberrant responses of insulin secretion and action to DM
progression and its severe consequences for whole body
metabolism and health outcomes.
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